gip/glp-1 agonist Potential Use of GLP-1 and Receptor Agonists for Respiratory Disorders: Where Are We at? How Three Types of GLP-1
Description
North America dominates the market landscape, supported by favorable reimbursement policies, advanced healthcare infrastructure, and high treatment adoption rates

Problems can occur if severe nausea, vomiting, or diarrhea cause dehydration
Circulation 1998;98:16105.PubMed 17

Parkman HP, Hasler WL, Fisher RS

While PD1 antagonist drugs currently reign as the top-selling drug class, this status quo is poised for a shift

[DOI] [PMC free article] [PubMed] [Google Scholar] 36.Li X., Liu Y., Zheng Y., Wang P., Zhang Y
